Last updated: April 24, 2026
What is “perflutren” in pharma supply chains?
Perflutren is the active substance used in ultrasound contrast products (primarily for echocardiography). In commercial products, it is typically supplied and handled as a stabilized injectable dispersion or formulation that enables safe delivery of perflutren gas microbubbles for imaging.
From a sourcing perspective, “perflutren suppliers” fall into three practical buckets:
- Finished dose manufacturers (brand/generic ultrasound contrast products that contain perflutren and are supplied under finished product distribution)
- API and formulation suppliers (entities that supply perflutren drug product components or the stabilized perflutren dispersion process intermediates, where applicable)
- Fill-finish and contract manufacturers (CRO/CMO fill-finish and manufacturing services for perflutren contrast products)
The market structure is dominated by a small number of established ultrasound contrast players and their contract or integrated manufacturing networks. Perflutren sourcing is typically exercised at the finished-product level unless a company is a licensed manufacturer with a validated formulation and regulatory pathway.
Which companies supply perflutren products used clinically?
The most direct, auditable “supplier” list is the finished product label holders and their marketed products.
| Ultrasound contrast product (perflutren-containing) |
Active |
Common market role |
Typical supplier channel for customers |
| Definity (US) |
Perflutren lipid microspheres |
Marketed finished product |
Contract purchasing from brand/generic distributors |
| Luminity (EU/other markets) |
Perflutren lipid microspheres |
Marketed finished product |
Distributor supply chain or local affiliate procurement |
| Optison (US) |
Perflutren protein-type A microspheres |
Marketed finished product |
Distributor supply chain or local affiliate procurement |
Who makes the branded perflutren contrast products?
The perflutren ultrasound contrast market is concentrated around the product families above and their branded supply chains.
| Product |
Manufacturer / label holder (commercially marketed entity) |
Sourcing implication |
| Definity |
Lantheus (brand platform) |
Purchasers buy through finished product distribution |
| Luminity |
Lantheus (brand platform in multiple regions) |
Purchasers buy through finished product distribution |
| Optison |
GE Healthcare historical platform (widely marketed in multiple periods) |
Purchasers buy through finished product distribution |
What supplier categories exist beyond brand procurement?
For procurement teams and R&D-facing sourcing, the relevant “suppliers” are often not “API vendors” in the way small-molecule API is sold. Instead, the supply chain is structured around manufacturing know-how and validated sterile product manufacture:
- Drug product manufacturers / fill-finish sites
- Steam sterilization, aseptic handling, vialing/syringe filling, and validated microbubble stabilization processes
- Raw material and lipid/component suppliers
- Supply of lipid excipients used to stabilize perflutren microbubbles in lipid-based formulations
- Packaging and sterile containment suppliers
- Vials, stoppers, syringes, and container closure systems compliant with injectable standards
Where does perflutren come from operationally?
Perflutren is a gas supplied under industrial gas logistics routes, then incorporated into the microbubble formulation by the licensed sterile manufacturer. In practice:
- The finished product manufacturer sources perflutren gas through qualified industrial gas channels or their corporate industrial procurement.
- The manufacturer then executes microbubble formation, stabilization, sterile processing, and final packaging under GMP.
As a result, the most reliable supplier list for buyers is the finished product supply chain, not a long list of unverified “API” vendors.
Procurement reality: finished product dominates demand
Most regulated buyers:
- Purchase Definity / Luminity / Optison as finished sterile injectables.
- Do not attempt direct “perflutren” chemical sourcing due to the need for sterile manufacturing, stabilization, and regulatory control.
For businesses building supply resilience:
- Supplier diversification is typically done at the finished product distributor and authorized manufacturer level, not at the raw-gas supplier level.
Key sourcing options for enterprises
1) Authorized distributor procurement (fastest path)
- Use region-licensed distributors carrying perflutren contrast products (Definity/Luminity/Optison depending on local approvals).
- This route reduces regulatory and GMP friction.
2) Direct purchase from manufacturer or local affiliates (highest control)
- Engage manufacturer sales or local affiliates for purchasing agreements and allocation planning.
3) CMO / CDMO for new entrants (longest path)
- If a company intends to commercialize perflutren contrast, it typically contracts manufacturing and fill-finish with an aseptic injectable capability validated for microbubble products.
- This is a project-based sourcing model rather than a commodity API supply model.
What should buyers ask suppliers for in perflutren contrast sourcing?
Procurement should require documentation tied to sterile injectable microbubble products:
- GMP batch records and release specifications for each lot
- Certificate of Analysis (CoA) and Certificate of GMP Compliance
- Container closure system compatibility and leak/sterility assurance documentation
- Stability data for the specific marketed formulation (lipid microspheres vs protein-type A microspheres)
Market structure summary
| Dimension |
What matters for perflutren |
| Dominant supply mode |
Finished sterile injectable contrast products |
| “Supplier” in practice |
Lantheus (Definity/Luminity) and legacy GE Healthcare platform (Optison) depending on region |
| Industrial inputs |
Perflutren gas plus stabilized microbubble excipients |
| Procurement strategy |
Distributor and authorized manufacturer diversification; CMO path for new entrants |
Key Takeaways
- Perflutren is sourced and delivered primarily through finished ultrasound contrast products, not commodity API purchasing.
- Commercial “perflutren suppliers” for most buyers are the branded product platforms: Lantheus (Definity and Luminity) and the GE Healthcare platform (Optison) depending on market.
- Raw inputs (perflutren gas and formulation excipients) still follow qualified supplier routes, but practical procurement for regulated customers centers on authorized finished product supply and verified batch documentation.
FAQs
1) Who are the main supplier entities for perflutren ultrasound contrast products?
Lantheus supplies the Definity and Luminity perflutren lipid microsphere brands, while Optison is the GE Healthcare legacy perflutren contrast product platform. (Product availability varies by jurisdiction.)
2) Can companies buy perflutren as an API from industrial vendors?
In practice, most customers buy finished sterile injectables because perflutren must be formulated into stabilized microbubbles under GMP with validated sterile manufacturing and release testing.
3) What form does perflutren take in commercial products?
It is formulated as ultrasound microbubble contrast, typically lipid microspheres (Definity/Luminity) or protein-type A microspheres (Optison), supplied as a sterile injectable.
4) What should a buyer verify when sourcing perflutren contrast?
Verify lot-level CoA, sterile release documentation, container closure integrity, and GMP compliance for the exact marketed formulation.
5) What is the fastest sourcing route for perflutren contrast?
Authorized procurement through licensed distributors carrying the relevant approved marketed product in the buyer’s region.
References
[1] Lantheus. Definity (perflutren lipid microsphere) prescribing information.
[2] Lantheus. Luminity (perflutren lipid microsphere) prescribing information.
[3] GE Healthcare. Optison (perflutren protein-type A microsphere) prescribing information.
[4] U.S. FDA. Drug label information for Definity, Luminity, and Optison (perflutren-containing ultrasound contrast agents).
